0001452804 false --09-30 2022 Q1 P2Y2M12D P2Y2M12D P2Y2M12D P2Y2M12D P1Y9M14D P1Y9M14D P1Y9M14D P1Y9M14D 0001452804 2021-10-01 2021-12-31 0001452804 2022-12-16 0001452804 2021-12-31 0001452804 2021-09-30 0001452804 2020-10-01 2020-12-31 0001452804 us-gaap:CommonStockMember 2020-09-30 0001452804 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001452804 us-gaap:RetainedEarningsMember 2020-09-30 0001452804 2020-09-30 0001452804 us-gaap:CommonStockMember 2021-09-30 0001452804 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001452804 us-gaap:RetainedEarningsMember 2021-09-30 0001452804 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001452804 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001452804 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001452804 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001452804 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001452804 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001452804 us-gaap:CommonStockMember 2020-12-31 0001452804 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001452804 us-gaap:RetainedEarningsMember 2020-12-31 0001452804 2020-12-31 0001452804 us-gaap:CommonStockMember 2021-12-31 0001452804 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001452804 us-gaap:RetainedEarningsMember 2021-12-31 0001452804 pkph:EntityControllerBySoleOfficerAndDirectorMember 2021-12-31 0001452804 pkph:EntityControllerBySoleOfficerAndDirectorMember 2021-09-30 0001452804 pkph:ConvertibleNotesPayable1Member 2017-03-17 0001452804 pkph:ConvertibleNotesPayable1Member 2021-12-31 0001452804 pkph:ConvertibleNotesPayable1Member 2021-09-30 0001452804 pkph:ConvertibleNotesPayable2Member 2017-03-30 0001452804 pkph:ConvertibleNotesPayable2Member 2021-12-31 0001452804 pkph:ConvertibleNotesPayable2Member 2021-09-30 0001452804 pkph:NotesPayable1Member 2018-01-10 0001452804 pkph:NotesPayable1Member 2021-12-31 0001452804 pkph:NotesPayable1Member 2021-09-30 0001452804 pkph:NotesPayable2Member 2018-04-02 0001452804 pkph:NotesPayable2Member 2021-12-31 0001452804 pkph:NotesPayable2Member 2021-09-30 0001452804 pkph:NotesPayable3Member 2021-06-14 0001452804 pkph:NotesPayable3Member 2021-12-31 0001452804 pkph:NotesPayable3Member 2021-09-30 0001452804 pkph:NotesPayable4Member 2021-09-30 0001452804 pkph:NotesPayable4Member 2021-12-31 0001452804 pkph:NotesPayable5Member 2021-09-30 0001452804 pkph:NotesPayable5Member 2021-12-31 0001452804 pkph:EmployeeMember 2021-10-01 2021-12-31 0001452804 pkph:NonEmployeeMember 2021-10-01 2021-12-31 0001452804 pkph:EmployeeMember 2021-12-31 0001452804 pkph:EmployeeMember 2021-09-30 0001452804 pkph:EmployeeMember 2020-10-01 2021-09-30 0001452804 pkph:NonEmployeeMember 2021-12-31 0001452804 pkph:NonEmployeeMember 2021-09-30 0001452804 pkph:NonEmployeeMember 2020-10-01 2021-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

þ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended ~~June~~December 3031, ~~2018~~2021

¨ o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from _________ to _________

Commission file number: 005-87668

PEAK PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada		26-1973257
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

14201 N. Hayden Road, Suite A-1, Scottsdale, AZ 85260

(Address of principal executive offices)

(480) 659-6404

(Registrant’s telephone number, including area code)

~~700~~ N~~. Colorado Blvd., #734, Denver, CO 80206~~/A

(Former address of principal executive offices)

~~Indicate by check mark whether the registrant~~Securities ~~(1)~~registered ~~has~~pursuant ~~filed all reports required~~ to ~~be filed by~~ Section ~~13 or 15~~12(db) of the ~~Securities Exchange~~ Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨:

~~Indicate~~Title ~~by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405~~ of ~~Regulation~~each ~~S-T~~class Trading symbol(§s) ~~232.405~~Name of ~~this~~exchange ~~chapter)~~on ~~during~~which ~~the~~registered ~~preceding~~None 12None ~~months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No þ~~None

~~Indicate by check mark whether the registrant~~Securities isregistered apursuant ~~large~~to ~~accelerated~~section ~~filer,~~12(g) ~~an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions~~ of ~~“large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of~~ the ~~Exchange~~ Act.:

~~Large~~Shares of ~~accelerated~~common ~~filer~~stock owith ~~Accelerated filer o Non-accelerated filer o Smaller reporting company þ (Do not check if~~ a ~~smaller~~par ~~reporting~~value ~~company)~~of ~~Emerging growth company □ o~~$0.0001

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) Title of ~~the Exchange Act. ¨~~class)

Indicate by check mark ~~whether~~if the registrant is a ~~shell~~well-known ~~company~~seasoned (issuer, as defined in Rule ~~12b-2~~405 of the ~~Exchange~~Securities Act). Yes ¨o No þ.x

AsIndicate by ofcheck ~~August~~mark ~~13,~~if ~~2018,~~the ~~there~~registrant ~~were~~is ~~78,363,562~~not ~~shares~~required ofto ~~registrant’s common~~file ~~stock~~reports ~~outstanding~~pursuant to Section 13 or Section 15(d) of the Act. Yes o No x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes o No x

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes o No x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o	Accelerated filer o

Non-accelerated Filer x	Smaller reporting company x

	Emerging growth company o

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes x No o

The number of shares outstanding of the registrant’s common stock as of December 16, 2022 was 78,363,567.

PEAK PHARMACEUTICALS, INC.

FORM 10-Q

FOR THE THREE ~~AND NINE~~ MONTHS ENDED ~~JUNE 30~~DECEMBER 31, ~~2018~~2021 ~~AND~~and ~~2017~~2020

TABLE OF CONTENTS

		Page
PART I. FINANCIAL INFORMATION
PART I.	FINANCIAL INFORMATION
ITEM 1	Financial Statements	3
ITEM 1.	Financial Statements (Unaudited)	3
	Condensed Consolidated Balance Sheets as of June 30, 2018 (unaudited) and September 30, 2017	3
	Condensed Consolidated Balance Sheets as of December 31, 2021 and September 30, 2021	3
	Condensed Consolidated Statements of Operations for the Three and Nine Months Ended June 30, 2018 and 2017 (unaudited)	4
	Condensed Consolidated Statements of Operations for the Three Months Ended December 31, 2021 and 2020	4
	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended June 30, 2018 and 2017 (unaudited)	5
	Condensed Consolidated Statements of Stockholders’ Deficit for the Three Months Ended December 31, 2021 and 2020	5
	Notes to Condensed Consolidated Financial Statements (unaudited)	6
	Condensed Consolidated Statements of Cash Flows for the Three Months Ended December 31, 2021 and 2020	6
ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	10
	Notes to Condensed Consolidated Financial Statements	7
ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk	15
ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12
ITEM 4.	Controls and Procedures	15
ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk	16
PART II. OTHER INFORMATION
ITEM 4.	Controls and Procedures	16
ITEM 1.	Legal Proceedings	17
PART II.	OTHER INFORMATION
ITEM 1A.	Risk Factors	17
ITEM 1.	Legal Proceedings	18
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	17
ITEM 1A.	Risk Factors	18
ITEM 3.	Defaults Upon Senior Securities	17
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18
ITEM 4.	Mine Safety Disclosures	17
ITEM 3.	Defaults Upon Senior Securities	18
ITEM 5.	Other Information	17
ITEM 4.	Mine Safety Disclosures	18
ITEM 6.	Exhibits	18
ITEM 5.	Other Information	18
SIGNATURES		19
ITEM 6.	Exhibits	19
SIGNATURES		20

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PEAK PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

~~AS OF JUNE 30, 2018~~(Unaudited)

(Unaudited)

	December 31,			September 30,
	2021			2021
Assets
Current assets:
Cash	$	187,554		$	261,152
Prepaid expenses		5,500			-
Total Assets	$	193,054		$	261,152

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities
Accounts payable (including $124,896 and $133,986 due to related parties)	$	197,291		$	214,136
Accrued liabilities		73,303			35,201
Convertible notes payable		10,000			20,000
Notes payable		263,000			283,000
Notes payable – related party		35,000			35,000
Total Liabilities		578,594			587,337

Stockholders’ deficit
Preferred stock, $0.0001 par value, 25,000,000 authorized, none issued or outstanding		-			-
Common stock, $0.0001 par value, 300,000,000 shares authorized, 78,363,567 shares issued and outstanding		7,836			7,836
Additional paid in capital		4,855,566			4,855,566
Accumulated deficit		(5,248,942	)		(5,189,587	)
Total Stockholders’ Deficit		(385,540	)		(326,185	)
Total Liabilities and Stockholders’ Deficit	$	193,054		$	261,152

	June 30,		September 30,
	2018		2017
			(Audited)
Assets
Current assets:
Cash	$	17,359	$	2,991
Total Assets	$	17,359	$	2,991
Liabilities and stockholders' deficit
Liabilities
Accounts payable	$	149,742	$	163,075
Accrued liabilities		13,727		7,601
Convertible notes payable		25,000		25,000
Note payable		43,000
Total Liabilities		231,469		195,676
Stockholders’ Deficit
Preferred stock, $0.00001 par value, 25,000,000 authorized, none issued or outstanding		-		-
Common stock, $0.0001 par value, 325,000,000 shares authorized, 78,363,562 shares issued and outstanding, as of June 30, 2018 and September 30, 2017		7,836		7,836
Additional paid in capital		4,855,566		4,855,566
Accumulated deficit		(5,077,511)		(5,056,087)
Total Stockholders’ Deficit		(214,109)		(192,685)
Total Liabilities and Stockholders’ Deficit	$	17,359	$	2,991

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

~~See the accompanying notes to the condensed consolidated financial statements~~ 3

~~The~~PEAK ~~accompanying~~PHARMACEUTICALS, ~~footnotes~~INC. ~~are~~CONDENSED anCONSOLIDATED ~~integral~~STATEMENTS ~~part of~~OF ~~these~~OPERATIONS ~~condensed consolidated financial statements.~~(Unaudited)


	For the Three Months Ended
	December 31,
	2021			2020
Operating expenses:
General and administrative (including fees paid to related party of $4,770 and $4,730)	$	52,063		$	4,972
Total operating expenses		52,063			4,972

Operating loss		(52,063	)		(4,972	)

Other expenses (income):
Interest expense (including related party interest of $132 and $0)		8,831			2,382
Gain on forgiveness of debt		(1,539	)		-
Total other expenses (income), net		7,292			2,382

Net loss	$	(59,355	)	$	(7,354	)

Per share information:
Weighted average shares outstanding - basic and diluted		78,363,567			78,363,567

Net loss per share - basic and diluted	$	(0.00	)	$	(0.00	)

~~PEAK~~The accompanying ~~PHARMACEUTICALS,~~footnotes ~~INC~~are an integral part of these unaudited condensed consolidated financial statements.

~~CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS~~4

PEAK PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT FOR THE THREE ~~AND NINE~~ MONTHS ENDED ~~JUNE 30~~DECEMBER 31, ~~2018~~2021 AND ~~2017~~2020 (Unaudited)

(Unaudited)


	Common Stock				Additional Paid		Accumulated
	Shares		Amount		In Capital		Deficit			Total
Balance, October 1, 2020		78,363,567	$	7,836	$	4,855,566	$	(5,113,498	)	$	(250,096	)

Net loss		-		-		-		(7,354	)		(7,354	)
Balance, December 31, 2020		78,363,567	$	7,836	$	4,855,566	$	(5,120,852	)	$	(257,450	)

Balance, October 1, 2021		78,363,567	$	7,836	$	4,855,566	$	(5,189,587	)	$	(326,185	)

Net loss		-		-		-		(59,355	)		(59,355	)
Balance, December 31, 2021		78,363,567	$	7,836	$	4,855,566	$	(5,248,942	)	$	(385,540	)

	For the Three Months Ended				For the Nine Months Ended
	June 30,				June 30,
	2018		2017		2018		2017
Operating expenses:
General and administrative	$	2,998	$	14,037	$	18,208	$	21,350
Interest expense		1,286		598		3,094		634
Total expenses		4,284		14,635		21,302		21,984
Operating income (loss)		(4,284)		(14,635)		(21,302)		(21,984)
Change in fair value of convertible debt		-		-		-		(5,000)
Net loss	$	(4,284)	$	(14,635)	$	(21,302)	$	(26,984)
Per share information:
Basic weighted average shares outstanding		78,363,562		78,363,562		78,363,562		78,363,562
Diluted weighted average shares outstanding		78,363,562		78,363,562		78,363,562		78,363,562
Net loss per share - basic and diluted	$	0.00	$	0.00	$	0.00	$	0.00

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

~~See the accompanying notes to the condensed consolidated financial statements~~ 5

~~The~~PEAK ~~accompanying~~PHARMACEUTICALS, ~~footnotes~~INC. ~~are~~CONDENSED anCONSOLIDATED ~~integral~~STATEMENTS ~~part of~~OF ~~these~~CASH ~~condensed~~FLOWS ~~consolidated~~FOR ~~financial~~THE ~~statements.~~THREE MONTHS ENDED DECEMBER 31, 2021 AND 2020 (Unaudited)

	2021			2020
Cash flows from operating activities:
Net loss	$	(59,355	)	$	(7,354	)
Adjustment to reconcile net loss to net cash used in operating activities:
Gain on forgiveness of debt		(1,539	)		-
Change in operating assets and liabilities:
Prepaids		(5,500	)		-
Accounts payable		(6,216	)		1,734
Accounts payable - related parties		(9,090	)		3,208
Accrued liabilities		38,102			2,382
Net cash used in operating activities		(43,598	)		(30	)

Cash flows from financing activities:
Payments on notes payable		(20,000	)		-
Payment on convertible note payable		(10,000	)		-
Net cash used in financing activities		(30,000	)		-

Net change in cash		(73,598	)		(30	)
Cash, beginning of period		261,152			408
Cash, end of period	$	187,554		$	378

Supplemental disclosure of cash flow information
Cash paid for interest	$	-		$	-
Cash paid for income taxes	$	-		$	-

~~PEAK~~The accompanying ~~PHARMACEUTICALS,~~footnotes ~~INC~~are an integral part of these unaudited condensed consolidated financial statements.

~~CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS~~6

~~FOR~~PEAK ~~THE~~PHARMACEUTICALS, ~~NINE~~INC. ~~MONTHS~~NOTES ~~ENDED~~TO ~~JUNE~~CONDENSED ~~30,~~CONSOLIDATED ~~2018~~FINANCIAL ~~AND 2017~~STATEMENTS (Unaudited)

~~(Unaudited)~~NOTE 1 – NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

	For the Nine Months Ended
	June 30,
	2018		2017
Cash flows from operating activities:
Net loss	$	(21,302)	$	(26,984)
Adjustment to reconcile net loss to net cash used in operating activities:
Change in fair value of convertible debt		-		5,000
Change in operating assets and liabilities:
Prepaids		-		(6,000)
Deposits		-		-
Accounts payable		(13,456)		36,984
Disposal of discontinued operations		-		(27,000)
Accrued liabilities		6,126		-
Net cash used in operating activities		(28,632)		(18,000)
Cash flows from financing activities:
Proceeds from issuance of notes payable		43,000		20,000
Net cash provided by financing activities		43,000		20,000
Net change in cash		14,368		2,000
Cash, beginning of period		2,991		1,304
Cash, end of period	$	17,359	$	3,303
Supplemental disclosure of cash flow information
Cash paid for interest	$	-	$	-
Cash paid for income taxes	$	-	$	-

The Company was incorporated in Nevada on December 18, 2007. After a number of name changes, we again, changed our name to Peak Pharmaceuticals, Inc. on December 23, 2014. This name was consistent with our business operations and plans relating to development, manufacturing and marketing of hemp-based nutraceutical and supplement products for the human and animal health markets. On October 1, 2015, we discontinued certain operations of the Company.

~~See~~The Company ~~the~~is ~~accompanying notes~~currently toa ~~the~~“shell ~~condensed~~company” ~~consolidated~~(as ~~financial~~such ~~statements~~ term is defined in Rule 12b-2 under the Exchange Act).

~~The~~Throughout this ~~accompanying~~report, ~~footnotes~~the ~~are~~terms an“our,” ~~integral~~“we,” ~~part~~“us,” and the “Company” refer to Peak Pharmaceuticals, ofInc. ~~these~~and ~~condensed~~its ~~consolidated~~wholly-owned ~~financial~~subsidiary, ~~statements~~Peak BioPharma Corp.

5Basis of Presentation

~~PEAK~~The accompanying ~~PHARMACEUTICALS~~unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles (“GAAP”) for interim financial statements, ~~INC~~instructions to Form 10-Q, and Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in our annual report on Form 10-K for the year ended September 30, 2021. In management’s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation to make our financial statements not misleading have been included. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year, or any other period.

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL~~Basis ~~STATEMENTS~~of Consolidation

~~(Unaudited)~~The unaudited condensed consolidated financial statements include the financial statements of the Company and our wholly owned subsidiary Peak BioPharma Corp. All inter-company balances and transactions among the companies have been eliminated upon consolidation.

~~NOTE 1 – NATURE OF OPERATIONS, BASIS OF PRESENTATION AND~~Use ~~SUMMARY~~of ~~OF SIGNIFICANT ACCOUNTING POLICIES~~Estimates

The ~~Company was incorporated~~ inpreparation ~~Nevada~~of onunaudited ~~December~~condensed ~~18,~~consolidated ~~2007.~~financial ~~After~~statements ain ~~number~~conformity ofwith ~~name~~U.S. ~~changes,~~GAAP werequires ~~again,~~management ~~changed~~to ~~our~~make ~~name~~estimates and toassumptions ~~Peak~~that ~~Pharmaceuticals,~~affect ~~Inc.~~the onamounts ~~December 23,~~of ~~2014.~~assets ~~This~~and ~~name~~liabilities ~~was~~and ~~consistent~~disclosure ~~with~~of ~~our~~contingent ~~business~~assets ~~operations~~ and ~~plans~~liabilities ~~relating~~at tothe ~~development,~~date ~~manufacturing and marketing~~ of the consolidated ~~hemp-based~~financial ~~nutraceutical~~statements and ~~supplement~~the ~~products~~reported ~~for~~amounts ~~the~~of ~~human~~expenses ~~and~~during ~~animal~~the ~~health~~reporting ~~markets~~period. OnActual ~~October~~results 1,could ~~2015, we discontinued~~differ ~~certain~~from ~~operations~~those ~~of the Company~~estimates.

~~Throughout~~Significant estimates ~~this~~made ~~report,~~ in connection with the ~~terms~~accompanying ~~“our,”~~consolidated ~~“we,”~~financial ~~“us,”~~statements ~~and~~include the ~~“Company”~~valuation ~~refer~~allowances toagainst ~~Peak~~net ~~Pharmaceuticals, Inc.~~deferred ~~and~~tax ~~its~~assets ~~subsidiary,~~and ~~Peak~~accounting ~~BioPharma~~for ~~Corp~~convertible debt.

~~Basis~~Loss Per ~~of Presentation~~Share

~~The accompanying unaudited~~We ~~condensed~~calculate ~~consolidated~~net ~~financial~~loss ~~statements~~per ofshare ~~the Company have been prepared~~ in accordance with ~~generally~~ASC ~~accepted~~Topic ~~accounting principles~~260, ~~(“GAAP”)~~Earnings ~~for~~per ~~interim~~Share. ~~financial~~Basic ~~statements,~~net ~~instructions~~loss toper ~~Form~~share ~~10-Q,~~is ~~and~~computed ~~Regulation~~by ~~S-X. Accordingly, certain~~dividing ~~information~~net ~~and~~loss ~~footnote~~by ~~disclosures~~the ~~normally~~weighted ~~included~~average innumber ~~financial~~of ~~statements~~shares ~~prepared~~of incommon ~~accordance~~stock ~~with~~outstanding ~~GAAP~~for ~~have~~the ~~been~~period, ~~condensed or~~and ~~omitted.~~diluted ~~These~~earnings ~~condensed~~per ~~consolidated~~share ~~financial~~is ~~statements~~computed by ~~should~~including becommon ~~read~~stock inequivalents ~~conjunction~~outstanding ~~with~~for the ~~financial~~period ~~statements and notes thereto included~~ in ~~our~~the ~~annual~~denominator. ~~report~~For ~~on Form 10-K for~~ the ~~year~~three months ended ~~September~~December 3031, ~~2017.~~2021 ~~In management's opinion~~and 2020, ~~all~~any ~~adjustments (consisting~~equivalents ~~only~~would ~~of normal recurring adjustments) considered necessary for a fair presentation to make our financial statements not misleading~~ have been ~~included.~~anti-dilutive ~~The~~as ~~results~~we ofhad ~~operations~~net losses for the ~~interim~~ periods ~~are~~then ~~not necessarily indicative of the results to be expected for the full year, or any other period~~ended.

~~Recent Pronouncements~~7

~~From~~As of ~~time~~September to30, ~~time~~2021, ~~new~~the Company had two convertible notes with principal and accrued interest balances totaling and $32,366. ~~accounting~~During ~~pronouncements~~the ~~are~~three ~~issued~~months ~~that~~ended weDecember ~~adopt~~31, as2021, the Company repaid one of these notes and related accrued interest totaling $15,408. As of December 31, 2021, the ~~specified~~Company ~~effective~~had ~~date~~one convertible note remaining with principal and accrued interest totaling $17,578. The Wenote ~~believe~~holders ~~that~~are entitled, at their option, to convert all or a part of their options at the ~~impact~~date into shares of ~~recently~~the ~~issued~~of common stock ~~standards~~in ~~that~~the ~~are~~Company ~~not~~at ~~yet~~a ~~effective~~price ~~may~~equal ~~have~~to ana ~~impact~~20% discount to the closing price of the common stock on ~~our~~the ~~results~~date of ~~operations~~the lender’s notice of conversion, subject to a floor of $0.01. These common stock equivalents of approximately 271,936 and ~~financial~~453,644 ~~position~~shares as of December 31, 2021 and 2020, respectively, are not included in the calculation of diluted EPS as their effect would be anti-dilutive.

~~In February 2016, the FASB~~As ~~issued~~of ~~ASU~~December ~~No. 2016-02~~31, ~~Leases,~~2021 ~~to improve financial reporting about leasing transactions. This ASU will require organizations that lease assets (“lessees”) to recognize a lease liability~~ and aSeptember ~~right-of-use~~30, ~~asset on its balance sheet for all leases with terms of more than twelve months. A lease liability is a lessee’s obligation to make lease payments arising from a lease~~2021, ~~measured on a discounted basis and a right-of-use asset represents~~ the ~~lessee’s~~Company ~~right~~had ~~to use~~3, ~~or control use of~~291, a000 ~~specified asset for the lease term. The amendments~~ in ~~this~~stock ~~ASU~~options ~~simplify~~outstanding ~~the~~which ~~accounting~~are ~~for~~exercisable ~~sale~~at ~~and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. This ASU leaves~~ the ~~accounting for the organizations that own~~holders’ ~~the assets leased to the lessee (“lessor”) largely unchanged except for targeted improvements to align it with the lessee accounting model and Topic 606~~option, ~~Revenue from Contracts~~ with ~~Customers.~~an ~~ASU~~exercise ~~No.~~price ~~2016-02~~of ~~is effective for reporting periods beginning after December 15~~$0.0067, ~~2018.~~which Weare do not ~~expect~~included in the ~~adoption~~calculation of ~~this~~diluted ~~guidance~~EPS toas ~~have~~their aneffect ~~impact~~would onbe ~~our consolidated financial statements~~anti-dilutive.

~~In April 2016, the FASB~~Recently ~~issued~~Issued ~~ASU~~Accounting 2016 – 10 “Revenue from Contract with Customers: identifying Performance Obligations and Licensing”. The amendments in this Update clarify the two following aspects (a) contracts with customers to transfer goods and services in exchange for consideration and (b) determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). The amendments in this Update are intended to reduce the degree of judgement necessary to comply with Topic 606. This guidance has no effective date as yet. The Company is currently evaluating the impact of adopting this guidance.Pronouncements

6Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

~~In August 2016, the FASB~~From ~~issued~~time ~~ASU~~to ~~2016-15~~time, ~~“Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments”. The~~ new ~~guidance~~accounting ispronouncements ~~intended~~are toissued ~~reduce~~that ~~diversity~~we inadopt ~~practice~~as inof ~~how certain transactions are classified in~~ the ~~statement~~specified ofeffective ~~cash flows~~date. ~~ASU~~We ~~2016-15~~believe isthat ~~effective for~~ the ~~Company~~impact ~~beginning in the first quarter~~ of recently ~~fiscal~~issued ~~2019.~~standards ~~Early adoption is permitted, provided~~ that ~~all of the amendments~~ are ~~adopted~~not inyet ~~the~~effective ~~same~~may ~~period.~~have ~~The~~an ~~guidance~~impact ~~requires~~on ~~application~~our ~~using~~results ~~a retrospective transition method. The Company is currently evaluating the impact~~ of ~~adopting~~operations ~~this~~and ~~guidance~~financial position.

InOn August ~~November~~5, ~~2016~~2020, the FASB issued Accounting Standards Update (ASU) ~~2016~~2020-1806, ~~“Statement~~Debt—Debt ofwith ~~Cash~~Conversion ~~Flows~~and ~~(Topic~~Other ~~230~~Options (Subtopic 470-20) ~~Restricted~~and ~~Cash”.~~Derivatives ~~The~~and ~~new~~Hedging—Contracts ~~guidance~~in ~~requires~~Entity’s ~~that~~Own ~~the~~Equity ~~reconciliation of~~(Subtopic ~~the beginning~~815-~~of-period~~40, ~~and~~which ~~end-of-period~~simplifies ~~amounts~~the ~~shown~~accounting for incertain ~~the~~financial ~~statement~~instruments with characteristics of ~~cash~~liabilities ~~flows~~and ~~include~~equity, ~~restricted~~including ~~cash~~convertible instruments and ~~restricted~~contracts on ~~cash~~an ~~equivalents.~~entity’s Ifown ~~restricted~~equity. ~~cash~~The isASU’s ~~presented~~amendments ~~separately~~are ~~from~~effective ~~cash~~for ~~and~~public ~~cash~~business ~~equivalents~~entities onthat ~~the~~are ~~balance~~not ~~sheet,~~smaller ~~companies~~reporting ~~will~~companies befor ~~required~~fiscal toyears ~~reconcile~~beginning ~~the~~after ~~amounts~~December ~~presented~~15, on2021, ~~the~~and ~~statement~~interim ofperiods ~~cash~~within ~~flows~~those tofiscal ~~the~~years. ~~amounts~~For onall other entities, the ~~balance~~amendments are ~~sheet.~~effective ~~Companies~~for ~~will also~~fiscal ~~need~~years tobeginning ~~disclose~~after ~~information~~December ~~about~~15, ~~the~~2023, ~~nature~~and ofinterim ~~the~~periods ~~restrictions~~within those fiscal years. The guidance ismay ~~effective~~be early adopted for fiscal years beginning after December 15, ~~2017~~2020, and interim periods within those fiscal years. The Company has determined that the adoption of this guidance has no impact on its consolidated financial statements.

In June ~~January 2017~~2016, the FASB issued ASU ~~2017~~No. 2016-0113, ~~“Business~~Financial ~~Combinations~~Instruments - Credit Losses (Topic ~~805~~326): ~~Clarifying~~Measurement ~~the~~of ~~Definition~~Credit ofLosses aon ~~Business~~Financial Instruments (“ASU 2016-13”). ~~The~~ASU ~~amendments~~2016-13 inamends ~~this~~the ~~Update is~~guidance toon ~~clarify~~ the ~~definition~~impairment of afinancial ~~business~~instruments. ~~with~~This update adds an impairment model (known as the ~~objective~~current ofexpected ~~adding~~credit ~~guidance~~losses tomodel) ~~assist~~that ~~entities~~is ~~with~~based ~~evaluating~~on ~~whether~~expected ~~transactions~~losses rather than incurred losses. ~~should~~Under bethe ~~accounted~~new ~~for~~guidance, an entity recognizes, as ~~acquisitions~~an ~~(or~~allowance, ~~disposals)~~its estimate of ~~assets~~expected orcredit ~~businesses~~losses. ~~The~~In ~~definition~~November of2019, athe ~~business~~FASB ~~affects~~issued ASU ~~many~~No. ~~areas of~~2019-10, ~~accounting~~Financial ~~including~~Instruments ~~acquisitions,~~- ~~disposals~~Credit Losses (Topic 326), ~~goodwill~~Derivatives and Hedging (Topic 815), and ~~consolidation~~Leases (Topic 842). ASU ~~The~~2019-10 ~~guidance~~changes isthe effective ~~for~~date ~~annual~~of ~~periods~~the credit loss standard (ASU 2016-13) to fiscal years beginning after December 15, ~~2017~~2022, including interim periods within those ~~periods~~fiscal years for smaller reporting companies. Further, the ASU clarifies that operating lease receivables are not within the scope of ASC 326-20 and should instead be accounted for under the new leasing standard, ASC 842. The Company has determined that the adoption of this guidance has no impact on its consolidated financial statements.

~~On May 10, 2017, the Financial~~Recently ~~Accounting~~Adopted ~~Standards Board (“FASB”) issued an~~ Accounting Standards Update (“ASU”) 2017-09 “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting”, which provides guidance to clarify when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The guidance is effective prospectively for all companies for annual periods beginning on or after December 15, 2017. Early adoption is permitted. The Company has determined that the adoption of this guidance has no impact on its consolidated financial statements.Pronouncements

~~NOTE~~In December 22019, the FASB issued ASU No. 2019-12, Income Taxes – ~~GOING~~Simplifying ~~CONCERN~~the ~~AND~~Accounting ~~MANAGEMENT’S~~for Income Taxes (Topic 740), ~~LIQUIDITY~~(“ASU ~~PLANS~~2019-12”), which simplifies income tax accounting in various areas including, but not limited to, the accounting for hybrid tax regimes, tax implications related to business combinations, and interim period accounting for enacted changes in tax law, along with some codification improvements. ASU 2019-12 is effective for interim and annual periods beginning after December 15, 2020. The Company adopted ASU 2019-12 on September 30, 2021 and has determined that the adoption of this guidance had no impact on its consolidated financial statements.

As of June 30, 2018, the Company had an accumulated deficit of $5,077,511 and a working capital deficiency of $214,110. During the nine months ended June 30, 2018, the Company used cash in operating activities of $28,632. As of June 30, 2018, the Company had cash of $17,359. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company recognizes it will need to raise additional capital in order to fund operations and meet its payment obligations. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company and whether the Company will generate revenues, become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds on favorable terms, it will have to develop and implement a plan to further extend payables and to raise capital through the issuance of debt or equity on less favorable terms until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.8

~~Accordingly~~In August 2018, the ~~accompanying consolidated~~FASB ~~financial~~issued ~~statements~~ASU ~~have~~No. ~~been~~2018-13, ~~prepared~~Disclosure inFramework ~~conformity~~– ~~with~~Changes ~~U.S.~~to ~~GAAP,~~the ~~which~~Disclosure ~~contemplates~~Requirements ~~continuation~~for ofFair ~~the~~Value ~~Company~~Measurement as(“ASU a2018-13”), ~~going~~which ~~concern~~eliminates ~~and~~certain ~~the~~disclosure ~~realization~~requirements offor ~~assets~~fair ~~and~~value ~~the~~measurements ~~satisfaction~~for ofall ~~liabilities~~entities, inrequires public ~~the~~entities ~~normal~~to ~~course~~disclose ofcertain ~~business~~new information and modifies some disclosure requirements. The ~~carrying~~guidance is effective for all entities ~~amounts~~for offiscal ~~assets~~years ~~and~~beginning ~~liabilities~~after ~~presented~~December in15, ~~the~~2019, ~~consolidated~~including ~~financial~~interim ~~statements~~periods dotherein. ~~not~~Early ~~necessarily~~adoption ~~represent~~is ~~realizable~~permitted orfor any eliminated ~~settlement~~or ~~values~~modified disclosures upon issuance of ASU 2018-13. The ~~consolidated~~Company ~~financial~~adopted ~~statements~~ASU do2018-13 ~~not~~on ~~include~~October ~~any~~1, ~~adjustments~~2020 ~~that~~and ~~might~~has ~~result~~determined ~~from~~that the adoption ~~outcome~~ of this ~~uncertainty~~ guidance had no impact on its consolidated financial statements.

7NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS

~~NOTE~~As of 3December –31, ~~RELATED~~2021, ~~PARTY~~the ~~TRANSACTIONS~~Company had an accumulated deficit of $5,248,942 and a working capital deficiency of $385,540. During the three months ended December 31, 2021, the Company incurred a net loss of $59,355 and used cash in operating activities of $43,598. As of December 31, 2021, the Company had cash of $187,554. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company recognizes it will need to raise additional capital in order to fund operations and meet its payment obligations. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company and whether the Company will generate revenues, become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds on favorable terms, it will have to develop and implement a plan to further extend payables and to raise capital through the issuance of debt or equity on less favorable terms until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.

~~Parties~~Accordingly, the ~~which~~accompanying ~~can~~unaudited becondensed ~~corporations or~~consolidated ~~individuals,~~financial ~~are~~statements ~~considered~~have tobeen beprepared ~~related~~in ifconformity ~~they~~with ~~have~~U.S. GAAP, which contemplates continuation of the ~~ability,~~Company ~~directly~~as ora ~~indirectly,~~going toconcern ~~control~~and the ~~other~~realization ~~party~~of orassets ~~exercise significant~~and ~~influence~~the ~~over~~satisfaction of liabilities in the ~~other~~normal ~~party~~course of business. The carrying amounts of assets and liabilities presented in ~~making~~the unaudited condensed consolidated financial ~~and~~statements ~~operating~~do not ~~decisions~~necessarily represent realizable or settlement values. ~~Companies~~The ~~are~~unaudited ~~also~~condensed ~~considered~~consolidated tofinancial bestatements ~~related if~~do ~~they~~not ~~are~~include ~~subject~~any adjustments tothat ~~common~~might ~~control~~result orfrom ~~common~~the ~~significant~~outcome ~~influence~~of this uncertainty.

~~Accounts~~NOTE 3 ~~payable~~ – ~~related~~ ~~parties~~RELATED ~~are~~PARTY the amounts payable to officers and directors of the Company for reimbursement of expenses they incurred on behalf of the Company as well as Directors’ fees and salaries. Included in accounts payable at June 30, 2018 are amounts totaling $47,877 (December 31, 2017 $47,877) owed to related parties.TRANSACTIONS

~~NOTE~~Parties, which 4can ~~–NOTES~~be ~~PAYABLE~~corporations or individuals, are considered to be related if they have the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

~~Loan~~Accounts payable – related parties are amounts payable to current and former officers and directors for services provided to the Company totaling $124,896 and $133,986, as of December 31, 2021 and September 30, 2021, respectively. These amounts include accounts payable to an entity controlled by our sole officer and director for financial services such entity is incurring on behalf of the Company totaling $50,019 and $59,109 as of December 31, 2021 and September 30, 2021, respectively. Total expense incurred related to this entity was $4,770 and $4,730 for the three months ended December 31, 2021 and 2020, respectively, with ~~Trius~~no ~~Holdings~~other ~~Limited~~related party expenses incurred.

~~On March 17, 2017, the~~NOTE ~~Company~~4 ~~entered~~– ~~into~~CONVERTIBLE anNOTES ~~agreement~~PAYABLE ~~with~~AND ~~Trius~~NOTES Holdings Limited (“Trius”). Pursuant to the terms of the agreement, Trius acquired a 12% convertible note with an aggregate face value of $10,000. The note matures in one year. Trius is entitled, at its option, to convert all or a part of the principal outstanding at the date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion, subject to a floor of $0.01. On May 11, 2018, the agreement had been amended to extend the maturing date of the note from March 21, 2018 to March 21, 2019.PAYABLE

~~Loan~~Convertible Notes ~~with Individual~~Payable

~~On March 30, 2017, the~~Loan ~~Company entered into an agreement~~ with anTrius ~~individual.~~Holdings Pursuant to the terms of the agreement, the individual acquired a 12% convertible note with an aggregate face value of $10,000. The note matures in one year. The individual is entitled, at its option, to convert all or a part of the principal outstanding at the date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion, subject to a floor of $0.01. On May 11, 2018, the agreement had been amended to extend the maturing date of the note from March 30, 2018 to March 30, 2019.Limited

~~Loan~~On March 17, 2017, the Company entered into an agreement with ~~Mediapark~~Trius ~~Investments~~Holdings Limited (“Trius”). Pursuant to the terms of the agreement, Trius acquired a 12% convertible note with an aggregate face value of $10,000. The note matures in one year and is unsecured. Trius is entitled, at its option, to convert all or a part of the principal outstanding at the date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion, subject to a floor of $0.01. On May 11, 2018, the agreement had been amended to extend the maturing date of the note from March 21, 2018 to March 21, 2019. As of December 31, 2021 and September 30, 2021, the total accrued interest owing under this note was $6,567 and $6,205, respectively. As of the date of this report, that date has not been extended, and the Company is accruing interest at the default interest rate of 15%.

On January 10, 2018, the Company entered into an agreement with Mediapark Investments Limited (“Mediapark”.) Pursuant to the terms of the agreement, Mediapark acquired a 12% promissory note with an aggregate face value of $23,000. The note matures in 180 days on July 10, 2018. As of July 9~~, 2018, the loan was extended to July 10, 2019.~~

Loan with Individual

On March ~~April 2~~30, ~~2018~~2017, the Company entered into an agreement with an individual. Pursuant to the terms of the agreement, wethe ~~received~~individual acquired a ~~promissory~~12% convertible note inwith ~~the~~an ~~amount~~ aggregate face value of $2010,000. The note ismatures ~~due~~in one year and ~~payable~~is unsecured. The individual is entitled, at its option, to convert all or a part of the principal outstanding at the date into shares of the of common stock in ~~full~~the Company at a price equal to a 20% discount to the closing price of the common stock on ~~October~~the 2date of the lender’s notice of conversion, subject to a floor of $0.01. The default interest rate is 15%. On May 11, 2018, the agreement had been amended to extend the maturing date of the note from March 30, 2018 to March 30, 2019. As of December 31, 2021 and itSeptember ~~accrues~~30, 2021, the total accrued interest atowing aunder this ~~rate~~note ofwas ~~12%~~$0 ~~per~~and ~~annum~~$6,160, respectively. On December 3, 2021, the Company repaid this loan and accrued interest in full.

~~Total accrued interest~~Notes ~~on the above notes was $4,336 as of June 30, 2018 (March 31, 2018 $3,049) and is reflected in accrued liabilities on the accompanying balance sheet.~~Payable

~~NOTE~~Loan with 5Mediapark –Investments ~~STOCKHOLDERS’ EQUITY~~ Limited

WeOn January ~~had~~10, no2018, ~~preferred~~the orCompany entered into an agreement with Mediapark Investments Limited (“Mediapark”.) Pursuant to the ~~common~~terms ~~stock~~of ~~transactions~~the ~~during~~agreement, Mediapark acquired a 12% promissory note with an aggregate face value of $23,000. The note matures in 180 days on July 10, 2018 and is unsecured. As of July 9, 2018, the ~~nine-month~~loan ~~period~~was ~~ended~~extended ~~June~~to July 10, 2019. As of December 31, 2021 and September 30, ~~2018~~2021, the total accrued interest owing under this note was $12,702 and ~~2017~~$11,813, respectively. As of the date of this report, that date has not been extended, and the Company is accruing interest at the default interest rate of 15%.

8 Loan with Individual

~~NOTE~~On April 62, –2018, ~~OPTIONS~~the Company entered into an agreement with an individual. Pursuant to the terms of the agreement, we received a promissory note in the amount of $20,000. The note is unsecured, is due and payable in full on October 2, 2018, and it accrues interest at a rate of 12% per annum. As of December 31, 2021 and September 30, 2021, the total accrued interest owing under this note was $0 and $9,883, respectively. On December 3, 2021, the Company repaid this loan and accrued interest in full.

~~No stock options were granted~~Loan ~~during~~with ~~the quarters ended June 30, 2018 and 2017.~~Officer

On June 14, 2021, the Company entered into an agreement with our sole officer and director. Pursuant to the terms of the agreement, we received a promissory note in the amount of $5,000. The ~~following~~note is aunsecured, ~~summary~~is due and payable in full on December 31, 2021, and accrues interest at a rate of ~~outstanding~~1.5% ~~stock~~per ~~options~~annum. ~~issued~~As toof ~~employees~~December 31, 2021 and ~~directors~~September as30, 2021, the total accrued interest owing under this note was $41 and $22, respectively. As of ~~June~~the 30date of this report, ~~2018:~~the due date has not been extended and the note is in default.

	Number of Options	Exercise Price per Share		Average Remaining Term in Years
Outstanding September 30, 2017 and June 30, 2018	2,916,000		$0.0067	5.70
Exercisable	2,916,000		$0.0067	5.70

During the three months ended September 30, 2021, the Company entered into a note payable with our sole officer and director for $30,000. The note is unsecured, is due and payable in full on December 31, 2021 and accrues interest at a rate of 1.5% per annum. As of December 31, 2021 and September 30, 2021, the total accrued interest owing under this note was $116 and $2. As of the date of this report, that date has not been extended, and the Company is accruing interest at the default interest rate of 10%.

~~The following is a summary~~Notes ofPayable ~~outstanding~~Issued ~~stock~~During ~~options~~the ~~issued~~Twelve toMonths ~~non-employees,~~Ended ~~excluding~~September ~~directors, as of June~~ 30, ~~2018:~~2021

	Number of Options	Exercise Price per Share		Average Remaining Term in Years
Outstanding September 30, 2017 and June 30, 2018	375,000		$0.0067	5.30
Exercisable	375,000		$0.0067	5.30

During the twelve months ended September 30, 2021, the Company entered into twelve notes payable totaling $240,000. The notes are unsecured, are due and payable in full on September 30, 2021, and accrue interest at a rate of 1.5% per annum. As of December 31, 2021 and September 30, 2021, the total accrued interest owing under these notes was $6,795 and $755. In June 2022, the Company repaid one of the notes with a principal balance of $35,000. As of the date of this report, that date has not been extended, and the Company is accruing interest at the default interest rate of 10%.

~~There was no equity-based compensation for the nine months ended June 30, 2018 and 2017.~~ 10

9NOTE 5 – OPTIONS

~~Item~~No stock 2.options ~~Management’s Discussion~~were ~~and~~granted ~~Analysis~~during ofthe ~~Financial~~three ~~Condition~~months ~~and~~ended ~~Results~~December of31, ~~Operations~~2021 and 2020.

~~Forward-Looking~~The following ~~Statements~~is a summary of outstanding stock options issued to employees and directors as of December 31, 2021 and September 30, 2021:

~~This~~Schedule report contains forward-looking statements. The following discussion should be read in conjunction with the financial statements and related notes contained in our Annual Report on Form 10-K, as filed with the Securities & Exchange Commission on January 12, 2018. Certain statements made in this discussion are "forward-looking statements" within the meaning of ~~The Private Securities Litigation Reform Act of 1995. Forward~~share-~~looking~~based ~~statements are projections in respect of future events or financial performance. In some cases~~compensation, ~~you can~~stock ~~identify forward-looking statements by terminology such as “may~~options,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology.activity

These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks in the section entitled “Risk Factors” set forth in our Annual Report on Form 10-K for the year ended September 30, 2017, as filed on January 12, 2018, any of which may cause our company’s or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These risks may cause the Company’s or its industry’s actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements.

	Number of Options		Exercise Price per Share		Average Remaining Term in Years
Outstanding December 31, 2021 and September 30, 2021		2,916,000	$	0.0067		2.20
Exercisable, December 31, 2021 and September 30, 2021		2,916,000	$	0.0067		2.20

~~Although the Company believes~~The ~~that~~following ~~the~~is ~~expectations~~a ~~reflected~~summary inof ~~the~~outstanding ~~forward-looking~~stock ~~statements~~options ~~are~~issued ~~reasonable~~to non-employees, itexcluding ~~cannot guarantee future results~~directors, ~~levels~~as of ~~activity~~ orDecember ~~performance. Moreover~~31, ~~neither~~2021 ~~the Company nor any other person assumes responsibility for the accuracy~~ and ~~completeness~~September of30, ~~these forward-looking statements. The Company is under no duty to update any forward-looking statements after the date of this report to conform these statements to actual results.~~2021:

AsSchedule ~~used~~of inshare-based ~~this quarterly report and unless otherwise indicated~~compensation, ~~the~~stock ~~terms “we~~options,” “us,” “our,” “Peak,” or the “Company” refer to Peak Pharmaceuticals, Inc, including our wholly-owned subsidiary Peak BioPharma Corp (“Peak BioPharma”). Unless otherwise specified, all dollar amounts are expressed in United States dollars.activity

Corporate Overview

	Number of Options		Exercise Price per Share		Average Remaining Term in Years
Outstanding December 31, 2021 and September 30, 2021		375,000	$	0.0067		1.79
Exercisable, December 31, 2021 and September 30, 2021		375,000	$	0.0067		1.79

~~We were incorporated as~~There ~~Surf~~was Ano ~~Movie~~equity-based ~~Solutions~~compensation ~~Inc.~~for inthe ~~Nevada~~three onmonths ended December 1831, ~~2007~~2021 ~~to engage in the business of the development, sales~~ and ~~marketing of online video stores~~2020. ~~We were not successful in our efforts and have ceased this line of business.~~

On October 10, 2013, we entered into a joint venture agreement with Produced Water Solutions, Inc., a Colorado corporation, that was in the business of providing economically and environmentally sound solutions for the treatment and recycling of wastewater resulting principally from oil and gas exploration and production activities. As a result of our research of this business opportunity, on December 31, 2013, we determined not to move forward with this line of business.11

~~In early March 2014, we~~ITEM entered into the business of developing, manufacturing and marketing pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of industrial hemp, for the prevention and alleviation of various conditions and diseases2. InMANAGEMENT’S ~~connection~~DISCUSSION ~~therewith,~~AND onANALYSIS ~~March~~OF ~~17,~~FINANCIAL ~~2014~~CONDITION weAND ~~changed~~RESULTS ~~our~~OF name to Cannabis Therapy Corp. On December 23, 2014, we changed our name to Peak Pharmaceuticals, Inc. All of our business operations are carried on through our wholly-owned subsidiary, Peak BioPharma Corp., a Colorado corporation.OPERATIONS

~~On July 29, 2014, through Peak BioPharma, we entered into a license agreement (the “License Agreement”) with Canna~~Forward-~~Pet, LLC (“Licensor”),~~Looking a Washington limited liability company, which owns the brand name “Canna-Pet” and certain related intellectual property including, but not limited to, trademarks and copyrights, formulations, recipes, production processes and systems, websites, domain names, customer lists, supplier lists, trade secrets and know-how, and other related intellectual property (collectively, the “Licensed Intellectual Property”), used by Licensor in the conduct of its business related to the production and sale of medical products made from industrial hemp which are intended exclusively for consumption by pets. Pursuant to the License Agreement, the Licensor granted to us a perpetual, exclusive, world-wide license to use the Licensed Intellectual Property in conjunction with our business and the production and sale of medical products made from industrial hemp as well as the right to sublicense the Licensed Intellectual Property to third parties. The License Agreement gives us the right to produce and sell existing products utilizing the Licensed Intellectual Property and to develop new products, jointly with Licensor or otherwise, based upon the Licensed Intellectual Property. The License Agreement provided us with an immediate revenue source and access to Licensor’s customer base. During the term of the license, all intellectual property rights in and to the Licensed Intellectual Property remained the exclusive property of Licensor.Statements

This report contains forward-looking statements. The following discussion should be read in conjunction with the financial statements and related notes contained in our Annual Report on Form 10 -K, as filed with the Securities & Exchange Commission on December 19, 2022. Certain statements made in this discussion are “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements are projections in respect of future events or financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology.

InThese statements ~~consideration~~are ofonly ~~the grant~~predictions ofand ~~the~~involve ~~license~~known and unknown risks, weuncertainties ~~agreed~~and toother ~~pay~~factors, ~~Licensor~~including ~~license~~the ~~fees~~risks in the ~~form~~section entitled of“Risk ~~royalty~~Factors” ~~payments~~set ~~calculated~~forth in our Annual Report on Form 10-K for the ~~basis~~year ended September 30, 2021, as filed on December 19, 2022, any of ~~gross~~which ~~proceeds~~may cause our company’s or our industry’s actual results, levels of activity, performance or achievements ~~received~~to bybe usmaterially different from ~~sales~~any offuture ~~products~~results, ~~manufactured~~levels of activity, ~~marketed~~performance or ~~sold~~achievements expressed or implied by usthese ~~utilizing~~forward-looking statements. These risks may cause the ~~Licensed~~Company’s ~~Intellectual~~or ~~Property~~its industry’s actual results, levels of activity or ~~any subsequently~~performance ~~developed~~to ~~intellectual~~be materially ~~property~~different ~~which~~from isany ~~jointly~~future ~~owned~~results, bylevels usof ~~and~~activity ~~Licensor.~~or Weperformance ~~began~~expressed ~~selling~~or ~~Canna-Pet~~implied ~~products~~by ~~in October~~these ~~2014~~forward-looking statements.

~~Based~~Although the ~~upon~~Company ~~recent~~believes ~~regulatory activity~~that ~~related~~the toexpectations ~~imposition~~reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of ~~restrictions~~activity ~~and~~or ~~limitations~~performance. onMoreover, neither the ~~sale~~Company ofnor ~~hemp-based~~any ~~health~~other ~~products~~person assumes responsibility for ~~pets,~~the weaccuracy ~~elected~~and tocompleteness ~~terminate~~of ~~our~~these ~~license~~forward-looking ~~agreement~~statements. ~~with~~The ~~the~~Company ~~Licensor,~~is ~~effective~~under asno ofduty ~~October~~to 1,update ~~2015,~~any ~~and~~forward-looking tostatements ~~cease~~after ~~all~~the ~~operations~~date ~~relating~~of tothis ~~sale~~report ofto ~~hemp-based~~conform ~~products~~these ~~for~~statements ~~pets~~to actual results.

OnAs used ~~October~~in ~~12,~~this ~~2015,~~quarterly ~~we entered~~report ~~into~~and anunless ~~agreement~~otherwise ~~for~~indicated, the ~~termination~~terms (“~~Termination~~we,” ~~Agreement~~“us,”) of“our,” “Peak,” or the ~~License~~“Company” ~~Agreement~~refer to Peak Pharmaceuticals, ~~effectively~~Inc, ~~selling the~~including ~~discontinued~~our ~~operations~~wholly-owned subsidiary Peak BioPharma Corp (“Peak BioPharma”). ~~The~~Unless ~~Termination~~otherwise ~~Agreement~~specified, ~~contained~~all ~~the~~dollar ~~following~~amounts ~~provisions:~~are expressed in United States dollars.

·Corporate History ~~Termination of License: The parties agreed to terminate the License Agreement effective as of October 1, 2015, this termination was made by mutual agreement of the parties pursuant to~~ and ~~in accordance with the provisions of the License Agreement.~~Overview

~~· Return of Licensed Intellectual Property:~~ We were ~~agreed~~first toincorporated ~~return~~in ~~all~~Nevada ~~Licensed~~as ~~Intellectual~~Surf ~~Property~~A toMovie ~~the Licensor~~Solutions, ~~and~~Inc. ~~our~~on ~~right~~December ~~to use all~~18, or2007 ~~any~~to ~~portion,~~engage ofin the ~~Licensed~~business ~~Intellectual Property ceased effective as~~ of ~~October~~the 1,development ~~2015,~~sale and ~~Pursuant~~marketing ~~to the terms~~ of ~~the~~online ~~License~~video ~~Agreement,~~sales. ~~the~~We ~~Licensed~~were ~~Intellectual~~not ~~Property~~successful ~~included~~in ~~the~~our ~~brand~~efforts ~~name “Canna-Pet”~~ and ~~certain~~discontinued ~~related~~this ~~intellectual~~line ~~property,~~of ~~including,~~business. ~~but~~Since ~~not~~that ~~limited,~~time ~~trademarks~~ and until ~~copyrights,~~August ~~formulations~~8, ~~recipes~~2014, ~~production~~we ~~processes~~were ~~and~~a ~~systems,~~“shell ~~websites,~~company” ~~domain~~(as ~~names,~~such ~~customer~~term ~~lists,~~is ~~supplier~~defined ~~lists~~in ~~trade~~Rule ~~secrets and know~~12b-2 ~~how,~~under ~~and~~the ~~other~~Exchange ~~related intellectual property~~Act).

·On August ~~Return~~30, of2013, ~~Other~~we ~~Property:~~changed Inour ~~addition~~name to ~~return~~Frac ofWater ~~the~~Systems, ~~Licensed~~Inc. ~~Intellectual Property~~and, weon ~~agreed~~October to10, ~~transfer~~2013, towe ~~Licensor~~decided ~~all~~to ~~product~~engage ~~inventory,~~in ~~Colorado~~the ~~hemp~~business ~~with~~of ~~permits~~providing economically and ~~authorization,~~environmentally ~~all~~sound ~~production/fulfillment~~solutions ~~contracts,~~for ~~all~~the ~~e-commerce~~treatment ~~accounts~~ and ~~processing,~~recycling ~~all~~of ~~non-disclosure~~wastewater ~~and~~resulting ~~research~~principally ~~agreements~~from oil and ~~any~~gas exploration and ~~all~~production ~~other~~activities. ~~property~~Due into our ~~possession~~research ~~which~~of ~~was used by us in~~ the ~~conduct of our~~ business ~~related~~opportunities, toon ~~production~~December ~~and~~31, ~~sale~~2013, ofwe ~~medical~~determined ~~cannabis~~not ~~products~~to move ~~for~~forward ~~pets~~with ~~made~~this ~~from~~line ~~hemp~~of ~~and low-THC cannabis plants~~business.

·In early ~~Office~~March ~~Space~~2014, ~~Equipment~~we decided to enter into the business of developing, manufacturing and ~~Employees:~~marketing Inpharmaceutical ~~conjunction~~level ~~with~~products ~~the~~containing phytocannabinnoids, ~~execution~~an abundant and pharmaceutically active component of industrial hemp, for the ~~Termination~~prevention ~~Agreement~~and alleviation of various conditions and diseases. In connection therewith, weon ~~granted~~March ~~the~~17, ~~Licensor~~2014, ~~the~~we ~~right~~changed our name to ~~use~~Cannabis ~~our~~Therapy ~~office~~Corporation ~~space~~and, ~~for~~on ~~the~~March 24, ~~three-month~~2014, ~~period~~changed ~~from~~our ~~October~~trading 1,symbol ~~2015~~on ~~through~~OTC Markets to “CTCO”. On December 3123, ~~2015~~2014, we changed our name to Peak Pharmaceuticals, Inc. and our trading symbol changed to “PKPH” on aFebruary ~~rent-free~~5, ~~basis~~2015.

·In March ~~Consideration:~~2014 Aswe ~~consideration~~began ~~for~~operating ~~the~~as ~~cancellation~~a ofbio-pharmaceutical ~~the~~and ~~License~~nutraceutical ~~Agreement~~company ~~and~~seeking ~~the~~to ~~return~~develop, ofmanufacture, ~~other~~market ~~property,~~and assell ~~described~~safe, high ~~above~~quality, ~~the~~medicinal ~~Licensor~~products ~~agreed~~based toon ~~waive~~extracts ~~payment~~from byhemp. usOur ~~and~~primary toinitial ~~release~~focus uswas ~~from~~on ~~liability~~exploitation ~~for~~of ~~payment~~the ofexclusive ~~any~~license we ~~and~~received ~~all~~from ~~unpaid~~Canna-Pet, ~~royalties~~LLC, ~~invoices~~a ~~and~~developer ~~other~~of ~~amounts~~ingestible ~~which~~health ~~were~~products ~~otherwise~~for ~~currently~~pets ~~due~~made ~~and~~from ~~payable~~hemp. byWe ushad toalso ~~Licensor~~taken ~~for~~initial ~~sales~~steps related to development of ~~Canna~~over-~~Pet~~the-counter, THC-free, hemp-based products for ~~all~~the ~~periods~~human ~~through~~market for the prevention and ~~including~~alleviation ~~September~~of ~~30,~~symptoms associated ~~2015~~with inflammatory and auto-immune diseases.

· Collections: On October 15, 2015, we forwarded to the Licensor all payments received by us after September 30, 2015 (net of amounts received by us for taxes, duties, governmental charges, freight or shipping charges, and the like) for Canna- Pet products sold on or after October 1, 2015.12

11On July 29, 2014, through our wholly-owned subsidiary, Peak BioPharma Corp., we entered into a License Agreement (the “License Agreement”) with Canna-Pet, LLC, (“Licensor”) a Washington limited liability corporation. They own the brand name “Canna-Pet” and certain related intellectual property including, but not limited to, trademarks and copyrights, formulations, recipes, production processes and systems, websites, domain names, customer lists, supplier lists, trade secrets and know-how, and other related intellectual property (collectively, the “Licensed Intellectual Property”). This is used by the Licensor in the conduct of its business related to the production and sale of medical products made from industrial hemp, which are intended exclusively for consumption by pets. Pursuant to the License Agreement, the Licensor granted to us a perpetual, exclusive, world-wide license to use the Licensed Intellectual Property in conjunction with our business and the production and sale of medical products made from industrial hemp, as well as the right to sublicense the Licensed Intellectual Property to third parties. The License Agreement gave us the right to produce and sell existing products utilizing the Licensed Intellectual Property and to develop new products, jointly with Licensor or otherwise, based upon the Licensed Intellectual Property. The License Agreement provided us with an immediate revenue source and access to Licensor’s customer base. The License Agreement specified that during the term of the license, all intellectual property rights in and to the Licensed Intellectual Property remain the exclusive property of Licensor.

~~The~~In consideration ~~following~~of isthe agrant ~~summary~~ of the ~~net~~license, ~~assets~~we ~~sold~~agreed asto ~~initially~~pay ~~determined~~Licensor atlicense ~~Septembers~~fees 30in the form of royalty payments calculated based on gross proceeds received by us from sales of products manufactured, ~~2015~~marketed or sold by us utilizing the Licensed Intellectual Property or any subsequently developed intellectual property which is jointly owned by us and ~~updated~~Licensor. ~~October~~We ~~15,~~began ~~2015:~~selling Canna-Pet products in October 2014.

	October 15, 2015		September 30, 2015
Inventory	$	45,436	$	41,705
Prepaid Expenses		8,821		-
Deposits		8,179		8,678
Total assets	$	62,436	$	50,383
Accounts payable		103,548		124,396
Royalties payable		39,506		39,506
Accrued liabilities		285		15,341
Total liabilities		143,339		179,243
Net assets sold	$	80,903	$	128,860

Based upon recent regulatory activity related to imposition of restrictions and limitations on the sale of hemp-based health products for pets, we elected to terminate our license agreement with the Licensor, effective as of October 1, 2015, and to cease all operations relating to sale of hemp-based products for pets.

~~Our~~On October ~~common~~12, ~~stock~~2015, iswe ~~currently~~entered into an agreement for the termination (“Termination Agreement”) of the License Agreement, effectively ~~listed~~selling the discontinued operations. Furthermore, based on advice from the ~~OTC~~Food ~~Markets~~and Drug Administration, QBas ~~Tier~~well as our regulatory counsel, we ~~under~~decided ~~the~~to ~~symbol~~revise our strategy and discontinue all efforts to develop and market hemp-based health products. We currently are pursuing to acquire or merge with an entity with significant operations in order to create a viable business model and value for our shareholders. Since October 2015 we have been a “~~PKPH~~shell company” (as such term is defined in Rule 12b-2 under the Exchange Act).

~~Recent~~All of ~~Corporate~~our ~~Developments~~business operations are carried out through our wholly owned subsidiary, Peak BioPharma Corp., a Colorado corporation. Throughout this Report, unless otherwise noted or required by the context, references to “the Company,” “us,” “we,” “our,” and similar terms refer to Peak Pharmaceuticals, Inc. and our wholly owned subsidiary, Peak BioPharma Corp.

~~Since~~We currently ~~the~~have ~~commencement~~authorized ~~of the year through June 30~~325, ~~2018~~000,000 weshares ~~received~~of ~~two~~capital ~~promissory~~stock, ~~notes.~~consisting ~~One~~of ~~promissory~~(i) ~~note was for $23~~300,000,000 onshares ~~January~~of 10common stock, ~~2018~~ and ~~the~~(ii) ~~other was for $20~~25,000,000 shares onof ~~April~~“blank 2,check” ~~2018~~Preferred Stock.

~~Loan~~On August ~~Agreements~~15, 2012, our board of directors and stockholders owning a majority of our outstanding common shares, authorized a 50 for 1 forward stock split of our issued and outstanding common stock. The forward split became effective on September 27, 2012. Due to the forward split, each outstanding share was split into 50 shares. On March 11, 2014, our board of directors authorized a 1.5 for 1 forward stock split of our common stock in the form of a dividend. In connection therewith, our shareholders of record as of the close of business on March 28, 2014, received an additional 0.5 share of our common stock for each share of our issued and outstanding common stock held by them on such date. The forward stock split became effective on April 1, 2014.

~~Loan~~Results of ~~with Trius Holdings Limited~~Operations

~~On March 17, 2017, we entered~~Comparison ~~into an agreement with Trius Holdings Limited. Pursuant to the terms~~ of the ~~agreement,~~Three ~~the~~Months ~~investor~~Ended ~~acquired~~December ~~a 12% convertible note with an aggregate face value of $10~~31,~~000.~~ ~~The~~2021 ~~note matures in one year. The holder of this note is entitled, at its option,~~ to ~~convert all or a part of~~ the ~~principal~~Three ~~outstanding~~Months atEnded ~~the~~December ~~date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion~~31, ~~subject to a floor of $0.01.~~2020

~~Loan with Individual~~13

On March 30, 2017, we entered into an agreement with an individual. Pursuant to the terms of the agreement, the investor acquired a 12% convertible note with an aggregate face value of $10,000. The note matures in one year. The holder of this note is entitled, at its option, to convert all or a part of the principal outstanding at the date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion, subject to a floor of $0.01.Revenue

~~Loan~~No revenue ~~with~~or ~~Mediapark~~cost ~~Investments~~of ~~Limited~~sales were generated for the three months ended December 31, 2021 or December 31, 2020.

~~On January 10, 2018, we~~Operating entered into an agreement with Mediapark Investments Limited. Pursuant to the terms of the agreement, the investor acquired a 12% promissory note with an aggregate face value of $23,000. The note matures in 180 days, on July 10, 2018.Expenses

~~Loan~~The Company’s ~~with~~expenses ~~Individual~~for the three months ended December 31, 2021 and 2020, are summarized as follows:

On April 2, 2018, the Company entered into an agreement with an individual. Pursuant to the terms of the agreement, we received a promissory note in the amount of $20,000. The note is due and payable in full on October 2, 2018 and it accrues interest at a rate of 12% per annum.

	Three Months Ended December 31,
	2021		2020
General and administrative (including $4,770 and $4,730 of fees paid to related party)	$	52,063	$	4,972
Total operating expenses	$	52,063	$	4,972

~~Total~~The increase ~~accrued~~in ~~interest on~~general and administrative expenses for the ~~above~~three ~~notes~~months ~~was~~ended $4December 31,~~336~~ as2021 ofcompared ~~June~~to ~~30,~~the ~~2018~~three ~~(March~~months ended December 31, ~~2018~~2020 of $347,~~049)~~091, ~~and~~ is ~~reflected~~due primarily to an increase in ~~accrued~~legal ~~liabilities~~fees related onto the ~~accompanying~~Company’s financing activities and ~~balance~~general ~~sheet~~corporate matters.

12Other Expenses

Results of Operations

	Three Months Ended December 31,
	2021			2020
Interest Expense (including related party interest of $132 and $0)	$	8,831		$	2,382
Gain on forgiveness of debt		(1,539	)		-
Total other expenses	$	7,292		$	2,382

~~Comparison~~Interest ofexpense increased $6,449 for the ~~Three~~three ~~Months~~months ~~Ended~~ended ~~June~~December 3031, ~~2018~~2021 from the comparative period of 2020 due primarily to an increase in the ~~Three~~Company’s ~~Months~~notes ~~Ended~~payable. ~~June~~The 30gain on forgiveness of debt of $1,539 ~~2017~~was a result of a decrease of accounts payable as a result of vendor adjustments.

~~Revenue~~Liquidity and Capital Resources

~~No revenue or cost of sales were generated for~~Working ~~the three months ended June 30, 2018 or June 30, 2017 due to the overall reduction in operations of the business.~~Capital

~~Operating~~The ~~Expenses~~following table sets forth a summary of changes in working capital as of ended December 31, 2021 and September 30, 2021:

Our expenses for the three months ended June 30, 2018 are summarized as follows in comparison to our expenses for the three months ended June 30, 2017:

	As of
	December 31, 2021			September 30, 2021
Current Assets	$	193,054		$	261,152
Current Liabilities		578,594			587,337
Working capital	$	(385,540	)	$	(326,185	)

	Three Months Ended June 30,
	2018		2017
General and administrative	$	2,998	$	14,037
Depreciation and amortization		-		-
Stock based compensation		-		-
Total operating expenses	$	2,998	$	14,037

The decrease in current assets of $68,098 is mainly due to a decrease in cash from the payment of outstanding bills and payment of a note payable of $30,000 during the three months ended December 31, 2021. The decrease in current liabilities of $8,743 is primarily due to a decrease in accounts payable and payments on notes payable during the three months ended December 31, 2021.

General and administrative expense decreased by $11,039 for the three months ended June 30, 2018 from the comparative period of 2017 due to the scaling down of business. Depreciation and amortization expense, as well as stock-based compensation were $0 for the three months ended June 30, 2018 and June 30, 2017.14

~~Comparison~~Cash ~~of the Nine Months Ended June 30, 2018 to the Nine Months Ended June 30, 2017~~Flows

~~Revenue~~The following table sets forth a summary of changes in cash flows for the three months ended December 31, 2021 and 2020:

No revenue or cost of sales were generated for the nine months ended June 30, 2018 or for the nine months ended June 30, 2017.

	Three Months Ended December 31,
	2021			2020
Net cash used in operating activities	$	(43,598	)	$	(30	)
Net cash used in financing activities		(30,000	)		-
Change in cash	$	(73,598	)	$	(30	)

~~Operating~~As ~~Expenses~~of December 31, 2021, our cash balance was $187,544. The Company does not expect its current cash and operating income to be sufficient to meet its financial needs for continuing operations over the next twelve months.

~~Our~~Net cash ~~expenses~~used in operations for the ~~nine~~ three months ended ~~June~~December 3031, ~~2018~~2021 ~~are~~of ~~summarized~~$43,598 aswas ~~follows~~mainly indue ~~comparison~~ to ~~our expenses for~~ the ~~nine~~net ~~months~~loss ~~ended~~that ~~June~~was ~~30,~~incurred ~~2017:~~during the period.

	Nine Months Ended June 30,
	2018		2017
General and administrative	$	18,208	$	21,350
Depreciation and amortization		-		-
Stock based compensation		-		-
Total operating expenses	$	18,208	$	21,350

Net cash used in financing activities for the three months ended December 31, 2021 of $30,000 was due to payment on notes payable during the period.

~~General~~We may ~~and~~need ~~administrative expense~~to ~~decreased~~evaluate byraising ~~$3,142~~additional ~~for~~capital through the ~~nine~~sale ~~months~~of ~~ended~~equity ~~June 30~~securities, ~~2018~~through ~~from~~an ~~the~~offering ~~comparative period~~ of ~~2017,~~debt ~~due~~securities toor ~~an overall decrease~~through inborrowing ~~business~~from ~~operations~~individuals. ~~Depreciation~~There ~~and~~can ~~amortization~~be ~~expense~~no asassurance ~~well~~that assuch ~~stock-based~~a ~~compensation~~plan ~~were~~will $0be successful.

13Cash Requirements

~~Other~~As ~~Expenses~~of the date of this filing, we do not have sufficient cash on hand to cover our operating expenses through the next fiscal year. As of December 16, 2022, we had cash and cash equivalents of approximately $97,000. Our liquidity needs have been satisfied primarily from the issuance of notes payable. The notes payable are unsecured, matured on September 30, 2021, have not been extended, and are currently in default. There can be no assurance, however, that additional financing will be available or, if it is available, that we will be able to structure such financing on terms acceptable to us and that it will be sufficient to fund our cash requirements until we can reach a level of profitable operations and positive cash flows. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses or experience unexpected cash requirements that would force us to seek additional financing. If additional financing is not available or is not available on acceptable terms, we will have to curtail our operations.

	Nine Months ended June 30,
	2018		2017
Interest Expense	$	3,094	$	634
Change in Fair Value of Convertible Debt		-		5,000
Total other expenses	$	3,094	$	5,634

Off-Balance Sheet Arrangements

~~Interest~~We have ~~expense~~no ~~increased from~~off-balance ~~$634~~sheet arrangements that have or are reasonably likely to ~~$3,094~~have ~~for~~a ~~the~~current ~~nine~~or ~~months~~future ~~ended~~effect ~~June~~on 30our financial condition, changes ~~2018~~in ~~from~~financial ~~the~~condition, ~~comparative~~revenues ~~period~~or expenses, results of ~~2017~~operations, ~~due~~liquidity, tocapital ~~additional~~expenditures ~~accrued~~or ~~interest~~capital resources that onis ~~the~~material ~~notes~~to stockholders.

~~Liquidity and Financial~~Effects ~~Condition~~of Inflation

~~Working~~We do ~~Capital~~not ~~Deficiency~~believe that inflation has had a material impact on our business, revenues or operating results during the periods presented.

		June 30, 2018		June 30, 2017
Current assets	$	17,359	$	2,991
Current liabilities		231,469		195,676
Working capital deficiency	$	(214,110)	$	(192,685)

Critical Accounting Policies and Estimates

~~The~~Our unaudited ~~increase~~condensed infinancial ~~current assets~~statements isand ~~mainly~~accompanying ~~due~~notes tohave ~~the~~been ~~receipt~~prepared ofin aaccordance ~~promissory~~with ~~note~~United ~~during~~States ~~the~~generally ~~nine~~accepted accounting ~~months~~principles ~~ended~~applied ~~June~~on ~~30,~~a ~~2018~~consistent basis. The ~~increase~~preparation of unaudited condensed financial statements in ~~current~~conformity ~~liabilities~~with U.S. isgenerally ~~due~~accepted accounting principles requires management to ~~transfer~~make ~~agent~~estimates and assumptions that affect the reported amounts of assets and liabilities, ~~filing~~the disclosure of contingent assets and ~~accounting~~liabilities ~~fees~~at ~~incurred~~the ~~for~~date of the ~~nine-month~~unaudited ~~period~~condensed ~~ending~~financial ~~June~~statements ~~30,~~and the ~~2018~~reported amounts of revenues and expenses during the reporting periods.

~~Cash Flows~~15

	Nine Months Ended June 30,
	2018		2017
Net income (loss)	$	(21,302)	$	(26,984)
Net cash provided (used) in operating activities		(28,632)		(18,000)
Net cash used in investing activities		-		-
Net cash provided by financing activities		43,000		20,000
Increase (decrease) in cash	$	17,359	$	3,303

We regularly evaluate the accounting policies and estimates that we use to prepare our unaudited condensed financial statements. A complete summary of these policies is included in the notes to our unaudited condensed financial statements, along with the related notes contained in our Annual Report on Form 10-K as filed with the Securities & Exchange Commission. In general, management’s estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.

~~As of June 30, 2018, our~~New ~~cash~~accounting ~~balance was $17,359. The Company does not expect its current cash and operating income to be sufficient to meet its financial needs for continuing operations over the next twelve months.~~standards

~~Net~~For discussion ~~cash~~of ~~used~~Recently inIssued ~~operations~~Accounting Pronouncements, ~~for~~see ~~the~~Note ~~nine~~1 ~~months~~to ~~ended~~the ~~June~~unaudited 30condensed financial statements, ~~2018~~“Nature ~~was~~of ~~$28~~Operations,~~632~~ ~~mainly~~Basis ~~due~~of aPresentation ~~decrease~~and Summary of Significant Accounting Policies” in ~~accounts~~Part ~~payable~~I, Item 1, of this Quarterly Report on Form 10-Q.

~~We need to raise additional~~ITEM ~~operating capital on an immediate basis. Although the expenses of our operations have been significantly reduced due to the termination of the license agreement as outlined in Note~~ 3 ~~of the financial statements, we need to still evaluate raising additional capital through the sale of equity securities, through an offering of debt securities or through borrowings from individuals~~. ~~There~~QUANTITATIVE ~~can be~~AND noQUALITATIVE ~~assurance~~DISCLOSURES ~~that~~ABOUT ~~such~~MARKET ~~a plan will be successful.~~RISK

~~As of the date of this~~Not ~~filing, we do not have enough sufficient cash on hand to cover our operating expenses through the next quarter~~applicable. In the absence of any ongoing commercial operations, we need enough cash to pay certain outside professionals to maintain our compliance under the Securities Act of 1934. Management anticipates that it will require an additional $30,000 over the next twelve months to cover such costs.

14ITEM 4. CONTROLS AND PROCEDURES

~~Going~~Evaluation ~~Concern~~of Disclosure Controls and Procedures

~~The condensed consolidated~~We ~~financial~~maintain ~~statements~~disclosure ~~contained~~controls inand ~~this~~procedures ~~report~~that ~~have~~are ~~been~~designed ~~prepared~~to ~~assuming~~ensure that ~~the~~material ~~Company~~information ~~will~~required ~~continue~~to asbe adisclosed ~~going~~in ~~concern.~~our ~~The~~periodic ~~Company~~reports ~~has~~filed ~~cumulative~~under ~~net~~the ~~losses~~Securities ~~through~~Exchange ~~June~~Act 30of 1934, ~~2018~~as ofamended, $5or 1934 Act,~~077~~ is recorded,~~511~~ processed, assummarized, ~~well~~and asreported ~~negative~~within the ~~cash~~time ~~flows~~periods ofspecified ~~$28,632~~in ~~from~~the ~~operating~~SEC’s rules and forms and to ensure that such information is accumulated and communicated to ~~activities.~~our ~~The~~management, ~~Company's~~including ~~cash~~our chief executive officer and ~~cash~~chief ~~equivalents~~financial ~~balance~~officer as appropriate, to allow timely decisions regarding required disclosure. At the end of ~~June~~the 30quarter ended December 31, ~~2018~~2021, iswe ~~$17~~carried out an evaluation,~~359.~~ ~~These~~under ~~factors~~the ~~raise~~supervision ~~substantial~~and ~~doubt~~with ~~about~~the participation of our management, including our principal executive officer and the ~~Company's~~principal ~~ability~~financial toofficer, ~~continue~~of asthe aeffectiveness of ~~going~~the ~~concern~~design and operation of our disclosure controls and procedures.

We do not have an audit committee: While we ~~will~~are ~~actively seek~~not currently obligated to ~~identify~~have ~~sources~~an ofaudit ~~liquidity~~committee, ~~there~~including ~~are~~a nomember ~~assurances~~who ~~that~~is ~~such~~an ~~additional~~“audit committee ~~sources~~financial ofexpert,” ~~liquidity~~as ~~can~~defined bein ~~obtained~~Item on407 ~~terms acceptable~~of toRegulation usS-K, onunder aapplicable ~~commercially~~regulations ~~reasonable~~or ~~basis,~~listing orstandards; athowever, it ~~all.~~is ~~These~~management’s ~~factors~~view ~~raise~~that ~~substantial~~such ~~doubt~~a ~~about~~committee ~~our~~is ~~ability~~an toimportant ~~continue as~~internal acontrol ~~going~~over ~~concern.~~financial ~~Furthermore~~reporting, ~~our~~the ~~“going~~lack ~~concern”~~of ~~and~~which ~~lack~~may result ofin ~~commercial~~ineffective ~~operations~~oversight ~~may~~in ~~make~~the itestablishment ~~more~~and ~~difficult~~monitoring ~~for us~~of tointernal ~~raise~~controls ~~funds~~and procedures.

~~The consolidated financial~~Based ~~statements~~on dothis ~~not~~evaluation, ~~include~~we ~~any~~determined ~~adjustments~~ that ~~may be necessary should the Company be unable to continue~~ as a going concern. The Company’s continuation as a going concern is dependent on its ability to obtain additional financing as may be required and ultimately to attain profitability. If the Company raises additional funds through the issuance of ~~equity,~~December ~~the percentage ownership of current shareholders could be reduced~~31, ~~and such securities might have rights~~2021, ~~preferences~~our ordisclosure ~~privileges~~controls ~~senior~~and toprocedures ~~its~~were ~~common stock. Additional financing may~~ not beeffective ~~available~~due ~~upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, the Company may not be able~~ to ~~take advantage of prospective business endeavors or opportunities, which could significantly and materially restrict its future plans for developing its business and achieving commercial revenues. If~~ the ~~Company is unable to obtain the necessary capital, the Company may have to cease operations.~~ following:

~~Off-Balance~~● ~~Sheet~~We ~~Arrangements~~do not have a majority of independent directors on our board of directors, which may result in ineffective oversight in the establishment and monitoring of required internal controls and procedures.

● We have noan ~~off-balance sheet~~inadequate ~~arrangements~~number ~~that~~of ~~have~~personnel ~~or are reasonably likely~~ to ~~have~~properly aimplement ~~current~~control or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholdersprocedures.

~~Effects~~● Due to the size and lack of ~~Inflation~~resources of our Company, we have not fully developed formal accounting policies and procedures.

● We dohave not ~~believe~~properly ~~that inflation~~complied ~~has~~with ~~had~~all aaspects ~~material~~of ~~impact~~the onInternal ~~our~~Control-Integrated ~~business,~~Framework ~~revenues~~issued orby ~~operating~~the ~~results~~Committee ~~during~~of Sponsoring Organizations of the ~~periods~~Treadway ~~presented~~Commission (COSO) in 2013.

~~Critical Accounting Policies and Estimates~~16

~~Our significant accounting~~Limitations ~~policies~~on ~~are~~Effectiveness ~~more~~of ~~fully~~Controls ~~described~~and ~~in the notes to our financial statements included herein for the nine months ended June 30, 2018.~~Procedures

~~Newly~~Our management, ~~Issued~~including ~~Accounting~~our ~~Pronouncements~~Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), does not expect that our disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

~~See Note 1 to our financial~~Changes ~~statements~~in ~~included~~Internal ~~herein~~Control ~~for~~Over ~~the~~Financial ~~nine months ended June 30, 2018 for a discussion of Recently Issued Accounting Pronouncements.~~Reporting

~~Item~~There were 3.no ~~Quantitative~~changes in our internal control over financial reporting during the three months ended December 31, 2021 that have materially ~~and~~affected ~~Qualitative~~or ~~Disclosures~~are ~~about~~reasonably ~~Market~~likely ~~Risk~~to materially affect our internal control over financial reporting.

~~Not applicable.~~17

~~Item~~PART II 4.– ~~Controls and~~OTHER ~~Procedures~~INFORMATION

~~Evaluation~~ITEM 1. ofLEGAL ~~Disclosure Controls and Procedures~~PROCEEDINGS

~~We maintain disclosure~~The ~~controls~~Company ~~and~~knows ~~procedures~~of ~~that~~no ~~are designed to ensure that~~ material ~~information~~pending ~~required~~legal proceedings to bewhich ~~disclosed in our periodic reports filed under~~ the ~~Securities~~Company ~~Exchange~~or ~~Act~~its ofSubsidiaries ~~1934,~~are asa ~~amended,~~party or ~~1934~~of ~~Act,~~which isany ~~recorded,~~of ~~processed,~~its ~~summarized~~properties, ~~and reported within~~ ~~the~~or ~~time periods specified in~~ the ~~SEC’s~~properties ~~rules~~of ~~and~~its ~~forms and to ensure that such information is accumulated and communicated to our management~~Subsidiaries, ~~including~~are ~~our~~the ~~chief executive officer and chief financial officer as appropriate, to allow timely decisions regarding required disclosure~~subject. AtIn ~~the end of the quarter ended June 30~~addition, ~~2018, we carried out an evaluation, under~~ the ~~supervision and~~Company ~~with~~does ~~the~~not ~~participation~~know of ~~our~~any ~~management,~~such ~~including~~proceedings ~~our~~contemplated ~~principal executive officer and the principal financial officer, of~~by ~~the~~any ~~effectiveness~~governmental ~~of the design and operation of our disclosure controls and procedures~~authorities.

15The Company knows of no material proceedings in which any of the Company’s directors, officers or affiliates, or any registered or beneficial stockholder is a party adverse to the Company or its Subsidiaries or has a material interest adverse to the Company or its Subsidiaries.

~~We do not have an audit~~ITEM ~~committee:~~1A. ~~While~~RISK we are not currently obligated to have an audit committee, including a member who is an “audit committee financial expert,” as defined in Item 407 of Regulation S-K, under applicable regulations or listing standards; however, it is management’s view that such a committee is an important internal control over financial reporting, the lack of which may result in ineffective oversight in the establishment and monitoring of internal controls and procedures.FACTORS

~~Based~~An investment onin ~~this~~the ~~evaluation,~~Company’s common stock involves a number of very significant risks. You should carefully consider the risk factors weincluded ~~determined~~in ~~that~~the as“Risk Factors” section of ~~June~~the Annual Report on Form 10-K for the year ended September 30, ~~2018~~2021 that was filed on December 19, ~~our~~2022, ~~disclosure~~in ~~controls~~addition to other information contained in those reports and ~~procedures~~in ~~were~~this ~~not~~quarterly ~~effective~~report in evaluating the Company and its business before purchasing shares of its common stock. The Company’s business, operating results and financial condition could be adversely affected due to ~~the~~any ~~following:~~of those risks.

·ITEM 2. WeUNREGISTERED doSALES ~~not~~OF ~~have~~EQUITY aSECURITIES ~~majority~~AND ofUSE ~~independent~~OF ~~directors on our board of directors, which may result in ineffective oversight in the establishment and monitoring of required internal controls and procedures.~~PROCEEDS

~~· We have an inadequate number of personnel to properly implement control procedures~~None.

·ITEM 3. ~~Due~~DEFAULTS toUPON ~~the~~SENIOR ~~size and lack of resources of our Company, we have not fully developed formal accounting policies and procedures.~~SECURITIES

~~· We have not properly complied with all aspects of the Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013~~None.

~~Limitations~~ITEM 4. onMINE ~~Effectiveness~~SAFETY ~~of Controls and Procedures~~DISCLOSURES

~~Our management, including~~Not our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), does not expect that our disclosure controls and procedures will prevent all errors and all fraudApplicable. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

~~Changes~~ITEM 5. inOTHER ~~Internal Control Over Financial Reporting~~INFORMATION

There were no changes in our internal control over financial reporting during the three months ended June 30, 2018 that have materially affected or are reasonably likely to materially affect our internal control over financial reportingNone.

1618

~~PART~~Item 6. ~~II – OTHER INFORMATION~~Exhibits

Item 1. Legal Proceedings

Exhibit
Number	Description
(2)	Plan of acquisition, reorganization, arrangement, liquidation or succession
2.1	Articles of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on September 5, 2013)
2.2	Agreement and Plan of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on September 5, 2013)
2.1	Articles of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on March 20, 2014)
2.2	Agreement and Plan of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on March 20, 2014)
2.1	Articles of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on December 30, 2014)
2.2	Agreement and Plan of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on December 30, 2014)
(3)	(i) Articles of Incorporation; and (ii) Bylaws
3.1	Articles of Incorporation (incorporated by reference to our Registration Statement on Form S-1 filed on December 29, 2008)
3.1.2	Certificate of Amendment to Articles of Incorporation (incorporated by reference to our Registration Statement on Form 10-K filed on December 26, 2012)
3.1.3	Certificate of Change (incorporated by reference to our Registration Statement on Form 10-K filed on December 26, 2012)
3.2	Bylaws (incorporated by reference to our Registration Statement on Form S-1 filed on December 29, 2008)
(4)	Instruments Defining the Rights of Security Holders, Including Indentures
4.1	Specimen Common Stock Certificate (incorporated by reference to our Registration Statement on Form S-1 filed on December 29, 2008)
4.1	Form of Registrant’s 10% Senior Convertible Promissory Note (incorporated by reference to our Registration Statement on Form 8-K filed on October 17, 2013)
(10)	Material Contracts
10.1	Convertible Promissory Note dated March 21, 2017 with Trius Holdings Limited (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on March 31, 2016.)
10.2	Convertible Promissory Note dated March 30, 2017 with Sukh Athwal (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on March 31, 2016.)
10.3	Convertible Promissory Note dated January 10, 2018 with Mediapark Investments Limited (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)
10.4	Convertible Promissory Note dated April 2, 2018 with Sukh Athwal (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)
10.5	First Amendment to Convertible Promissory Note dated May 7, 2018 with Sukh Athwal (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)
10.6	First Amendment to Convertible Promissory Note dated May 7, 2018 with Trius Holdings Limited (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)
10.7	Promissory Note dated June 14, 2021 with Neil Reithinger (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on December 19, 2022)
10.8	Promissory Note dated June 16, 2021 with Scott Lauer (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on December 19, 2022)
10.9	Promissory Note dated June 30, 2021 with Utopia Capital, LLC (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on December 19, 2022)
10.10	Promissory Note dated July 6, 2021 with Church & Keeler, Inc. (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.11	Promissory Note dated July 6, 2021 with Draper, Inc. (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.12	Promissory Note dated July 6, 2021 with Happy David Walters (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.13	Promissory Note dated July 9, 2021 with Carriage House Capital, Inc. (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.14	Promissory Note dated July 22, 2021 with John Walters Nick, Jr. (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.15	Promissory Note dated July 22, 2021 with Gary Goodman (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.16	Promissory Note dated July 26, 2021 with Stefan Galluppi (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.17	Promissory Note dated August 4, 2021 with Justin Schreiber (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.18	Promissory Note dated August 6, 2021 with Alexander Lim (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.19	Promissory Note dated August 12, 2021 with Aliunde Limited (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.20	Promissory Note dated September 28, 2021 with Neil Reithinger (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
(31)	Rule 13a-14(a)/15d-14(a) Certification
31.1*	Section 302 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer
31.2*	Section 302 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer
(32)	Section 1350 Certification
32.1*	Section 906 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer
32.2*	Section 906 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer
(101)*	Interactive Data Files
101.INS	Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document)
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

The Company knows of no material pending legal proceedings to which the Company or its Subsidiaries are a party or of which any of its properties, or the properties of its Subsidiaries, are the subject. In addition, the Company does not know of any such proceedings contemplated by any governmental authorities.

*	Filed herewith.

**	Furnished herewith. Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of any registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, and otherwise are not subject to liability under those sections.

The Company knows of no material proceedings in which any of the Company’s directors, officers or affiliates, or any registered or beneficial stockholder is a party adverse to the Company or its Subsidiaries or has a material interest adverse to the Company or its Subsidiaries.19

~~Item 1A. Risk Factors~~SIGNATURES

AnPursuant to ~~investment in~~ the ~~Company’s common~~requirements ~~stock involves a number~~ of ~~very significant risks. You should carefully consider~~ the ~~risk~~Securities ~~factors~~Exchange ~~included~~Act ~~in the “Risk Factors” section~~ of ~~the~~1934, ~~Annual Report on Form 10-K for~~ the ~~year~~registrant ~~ended~~has ~~September~~duly ~~30,~~caused ~~2017 that was filed on January 12, 2018, in addition to other information contained in those reports and in~~ this ~~quarterly~~ report into ~~evaluating~~be ~~the~~signed ~~Company~~on ~~and~~ its ~~business~~behalf by ~~before~~the ~~purchasing shares of its common stock. The Company’s business~~undersigned, ~~operating~~thereunto ~~results~~duly ~~and financial condition could be adversely affected due to any of those risks~~authorized.

~~Item 2. Unregistered Sales of Equity~~PEAK ~~Securities~~PHARMACEUTICALS, ~~and Use Of Proceeds~~INC.

None.

By:	/s/ Neil Reithinger
Neil Reithinger
Chief Executive Officer and Chief Financial Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
Date: December 19, 2022

~~Item 3. Defaults upon Senior Securities~~20

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit
Number	Description
(2)	Plan of acquisition, reorganization, arrangement, liquidation or succession
2.1	Articles of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on September 5, 2013)
2.2	Agreement and Plan of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on September 5, 2013)
2.1	Articles of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on March 20, 2014)
2.2	Agreement and Plan of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on March 20, 2014)
2.1	Articles of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on December 30, 2014)
2.2	Agreement and Plan of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on December 30, 2014)
(3)	(i) Articles of Incorporation; and (ii) Bylaws
3.1	Articles of Incorporation (incorporated by reference to our Registration Statement on Form S-1 filed on December 29, 2008)
3.1.2	Certificate of Amendment to Articles of Incorporation (incorporated by reference to our Registration Statement on Form 10-K filed on December 26, 2012)
3.1.3	Certificate of Change (incorporated by reference to our Registration Statement on Form 10-K filed on December 26, 2012)
3.2	Bylaws (incorporated by reference to our Registration Statement on Form S-1 filed on December 29, 2008)
(4)	Instruments Defining the Rights of Security Holders, Including Indentures
4.1	Specimen Common Stock Certificate (incorporated by reference to our Registration Statement on Form S-1 filed on December 29, 2008)
4.1	Form of Registrant’s 10% Senior Convertible Promissory Note (incorporated by reference to our Registration Statement on Form 8-K filed on October 17, 2013)
(10)	Material Contracts
10.1*	Convertible Promissory Note dated March 21, 2017 with Trius Holdings Limited
10.2*	Convertible Promissory Note dated March 30, 2017 with Sukh Athwal
10.3	Convertible Promissory Note dated January 10, 2018 with Mediapark Investments Limited (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)
10.4	Convertible Promissory Note dated April 2, 2018 with Sukh Athwal (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)
10.5	First Amendment to Convertible Promissory Note dated May 7, 2018 with Sukh Athwal (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)
10.6	First Amendment to Convertible Promissory Note dated May 7, 2018 with Trius Holdings Limited (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)
(31)	Rule 13a-14(a)/15d-14(a) Certification
31.1*	Section 302 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer
31.2*	Section 302 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer
(32)	Section 1350 Certification
32.1*	Section 906 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer
32.2*	Section 906 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer
(101)*	Interactive Data Files
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

Filed herewith.

Furnished herewith. Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of any registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, and otherwise are not subject to liability under those sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PEAK PHARMACEUTICALS, INC.

By: /s/ Neil Reithinger Neil Reithinger Chief Executive Officer and Chief Financial Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer) Date: August 13, 2018

Filing Compare · Retrieve Medical Holdings, Inc.